Table 5.
Baseline characteristics of the patients with and without C316N variant
| Baseline characteristics | Wild type (n = 8) | Mutation type (n = 129) | P |
|---|---|---|---|
| Age (year), median (range) | 45 (38–54) | 50 (23–67) | 0.600 |
| Male, n (%) | 55 (50) | 4 (100) | 0.150 |
| BMI (kg/m2), average (range) | 22.3 (22.0–30.6) | 26.4 (16.9–32.2) | 0.780 |
| ALT (U/L), median (range) | 66 (63–155) | 223.5 (16–404) | 0.070 |
| AST (U/L), median (range) | 34 (33–192) | 137 (18–292) | 0.380 |
| PLT count (×109/L), mean ± SD | 202 ± 60 | 214 ± 30 | 0.790 |
| AST/PLT, mean ± SD | 0.18 ± 0.05 | 0.59 ± 0.40 | 0.470 |
| Hemoglobin (g/dl), median (range) | 171.5 (163–175) | 144.5 (95–177) | 0.004 |
| Response to Peg-IFN plus RBV | |||
| SVR (n = 77) | 2 | 75 | 0.040 |
| Treatment-failures (n = 60) | 7 | 53 | |
| IL28B genotype | |||
| CC (n = 103) | 5 | 98 | 0.300 |
| CT (n = 34) | 4 | 30 | |
| Baseline HCV RNA >800,000 (IU/ml), n (%) | 6 (75) | 112 (86.8) | 0.700 |
BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; PLT: Platelet; Peg-IFN: Pegylated interferon; RBV: Ribavirin; SVR: Sustained virological response; HCV: Hepatitis C virus.